贝美前列素治疗原发性开角型青光眼和高眼压症的最小成本分析  

Assessment of the Cost Minimization of Bimatoprost in Treatment of Primary Open-angle Glaucoma and High Intraocular Pressure Disease

作　　者：杨兴华[1] 

机构地区：[1]首都医科大学,北京100069

出　　处：《药物流行病学杂志》2010年第10期574-577,共4页Chinese Journal of Pharmacoepidemiology

摘　　要：目的:对贝美前列素滴眼液与同类对照药物拉坦前列素滴眼液治疗原发性开角型青光眼和高眼压症进行药物经济学评价。方法:应用最小成本分析,对参加多中心临床试验医院采用回顾性调查收集费用数据并进行测算。结果:从药物费用上比较两药6周费用之差33.52～35.28元,从6个月诊疗总费用上看,贝美前列素滴眼液的诊疗费用439.6～918.3元,拉坦前列素滴眼液的诊疗费用680.8～1 062.0元,诊疗总费用在四个地区情况均为贝美前列素低于拉坦前列素。结论:贝美前列素滴眼液治疗相比于拉坦前列素治疗是经济的治疗方案,值得推荐应用。Objective： To assess the cost minimization of bimatoprost and latanoprost in the treatment of the primary open-angle glaucoma and high intraocular pressure disease. Method： By using the cost minimization analysis , the data of bimatoprost＇ s costs collected using the retrospective survey in multi-centered trial hospitals were previously analyzed. Result：The difference of bimatoprost and latanoprost＇ s medicinal costs was 33.52 - 35.28 yuan in 6 weeks. During 6 months＇ treatment, the cost of diagnosis and bimatoprost was 439.6 - 918.3 yuan, and latanoprost＇ s, 680.8 - 1 062 yuan. In 4 regions＇ hospitals, the cost of diagnosis and bimatoprost was always lower than latanoprost＇ s. Conclusion： This study demonstrated that bimatoprost＇ s cost was lower than latanoprost＇ s, and the former is worth applying and recommending.

关 键 词：贝美前列素 原发开角型青光眼 最小成本分析 拉坦前列素 

分 类 号：F407.7[经济管理—产业经济]